Teleflex Secures FDA Clearance For Wattson Temporary Pacing Guidewire
Portfolio Pulse from Benzinga Newsdesk
Teleflex has secured FDA clearance for its Wattson Temporary Pacing Guidewire, designed for use during TAVR and BAV procedures. The product will be featured at the TVT: The Structural Heart Summit and is expected to have a full market release later this year.
June 07, 2023 | 10:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Teleflex's FDA clearance for the Wattson Temporary Pacing Guidewire may boost its market position in the TAVR and BAV space, potentially leading to increased revenues.
The FDA clearance for Teleflex's Wattson Temporary Pacing Guidewire is a significant milestone for the company, as it allows them to enter the TAVR and BAV market with a unique product. This could lead to increased market share and revenues for Teleflex in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100